Sponsor Deadline
Posted: 4/18/2022

Next Generation Imaging Using Serial 18F-flutemetamol PET to Assess Diagnostic Performance and/or Disease Stabilization in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treated with Tafamidis

GE Healthcare and Pfizer are collaborating to offer a new competitive grant opportunity focused on addressing diagnostic performance and disease stabilization using 18F-flutemetamol cardiac PET in subjects presenting with ATTR-CM and are treated with Tafamidis.

Amyloid PET tracers such as 18F-flutemetamol could be a promising tool in the diagnosis and/or therapeutic response for patients with cardiac amyloidosis.  However, further data is needed to define the overall performance and additive value to current standard of care diagnostics in the care of patients with suspected systemic and/or ATTR cardiac amyloidosis.

Through this Research RFP, Pfizer and GE Healthcare wish to support research projects focused on assessing both diagnostic performance and changes over time of 18F-flutemetamol cardiac uptake after initiation of Tafamidis treatment in subjects diagnosed with ATTR cardiac amyloidosis.

Collaborations within institutions (e.g., between departments and/or inter-professional), as well as between different institutions / organizations / associations, are encouraged. Please note all partners must have a relevant role and the requesting organization must have a key role in the project.

Application Submission Deadline: February 1st, 2021 (Deadline Extended from Dec. 29)

Eligibility Requirements

Geographic Scope • United States

To be eligible: • Please e-mail amanda.j.stein@pfizer.com to confirm eligibility and radiopharmaceutical availability • The institution and principal investigator (PI) must be based in one of the eligible countries noted above. • Only organizations are eligible to receive grants, not individuals or medical practice groups. • The applicant (PI) must have a medical or postdoctoral degree (MD, PhD, or equivalent). • Applicant must be affiliated with a host institution

Amount Description

Individual projects requesting up to $125,000 will be considered. Pfizer and GE Healthcare anticipate awarding up to 2 grant(s).

Amount
$125,000
Funding Type
Eligibility
Posted
4/18/2022
Deadline
Sponsor: